Special agents hunting down women silent killer: The emerging role of the p38 kinase

Journal of Oncology

Volumn , Issue , 2012, Pages

  Grossi, Valentina ^a   Simone, Cristiano ^a  

^a Consorzio Mario NegriSud ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE INHIBITOR; AURORA A KINASE; BETA CATENIN; BEVACIZUMAB; BRCA1 PROTEIN; BRCA2 PROTEIN; CARBOPLATIN; CEDIRANIB; CISPLATIN; ERLOTINIB; ESTROGEN RECEPTOR ALPHA; FIBROBLAST GROWTH FACTOR 1; GEFITINIB; GEMCITABINE; INTERLEUKIN 6; LYSOPHOSPHATIDIC ACID; MISMATCH REPAIR PROTEIN PMS2; MITOGEN ACTIVATED PROTEIN KINASE 14; OLAPARIB; PACLITAXEL; PAZOPANIB; PERIFOSINE; PERTUZUMAB; PROTEIN P53; SORAFENIB; SUNITINIB; TRASTUZUMAB; VASCULOTROPIN A; ZINC FINGER PROTEIN;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CELL CYCLE; CELL CYCLE ARREST; CELL GROWTH; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMOSOME ABERRATION; CLINICAL TRIAL (TOPIC); DISEASE ASSOCIATION; DNA METHYLATION; DNA REPAIR; ENDOMETRIOID CARCINOMA; FEMALE; GENE EXPRESSION; GENE MUTATION; GYNECOLOGIC CANCER; HEREDITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LIPOGENESIS; MISMATCH REPAIR; ONCOGENE; OVARY CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; TUMOR SUPPRESSOR GENE;

EID: 84859798330     PISSN: 16878450     EISSN: 16878469     Source Type: Journal    
DOI: 10.1155/2012/382159     Document Type: Review

References (73)

1. Yap T. A., Carden C. P., Kaye S. B., Beyond chemotherapy: targeted therapies in ovarian cancer Nature Reviews Cancer 2009 9 3 167 181
2. Berek J. S., Berek J. S., Hacker N. F., Epithelial ovarian cancer Practical Gynecologic Oncology 4th edn Ch. 11 Ovarian Cancer 2005 Philadelphia, Pa, USA Lippincott Williams Wilkins 443 511
3. Watson P., Lynch H. T., Extracolonic cancer in hereditary nonpolyposis colorectal cancer Cancer 1993 71 3 677 685 (Pubitemid 23051366)
4. Rubin S. C., Blackwood M. A., Bandera C., Behbakht K., Benjamin I., Rebbeck T. R., Boyd J., Gallion H. H., Leslie K. K., Runowicz C. D., Hopkins M. P., BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing American Journal of Obstetrics and Gynecology 1998 178 4 670 677 (Pubitemid 28196872)
5. Singer G., Oldt R. III, Cohen Y., Wang B. G., Sidransky D., Kurman R. J., Shih I. M., Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma Journal of the National Cancer Institute 2003 95 6 484 486 (Pubitemid 36432423)
6. Nakayama K., Nakayama N., Kurman R. J., Cope L., Pohl G., Samuels Y., Velculescu V. E., Wang T. L., Shih I. M., Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms Cancer Biology and Therapy 2006 5 7 779 785 (Pubitemid 44775134)
7. Dinulescu D. M., Ince T. A., Quade B. J., Shafer S. A., Crowley D., Jacks T., Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer Nature Medicine 2005 11 1 63 70 (Pubitemid 40215839)
8. Oliva E., Sarri E. F., Brachtel E. F., Snches-Estévez C., Soslow R. A., Moreno-Bueno G., Palacios J., High frequency of -catenin mutations in borderline endometrioid tumours of the ovary Journal of Pathology 2006 208 5 708 713
9. Wu R., Hendrix-Lucas N., Kuick R., Zhai Y., Schwartz D. R., Akyol A., Hanash S., Misek D. E., Katabuchi H., Williams B. O., Fearon E. R., Cho K., Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/ -catenin and PI3K/Pten signaling pathways Cancer Cell 2007 11 4 321 333 (Pubitemid 46518315)
10. Cheng K. W., Lahad J. P., Gray J. W., Mills G. B., Emerging role of RAB GTPases in cancer and human disease Cancer Research 2005 65 7 2516 2519 (Pubitemid 40490043)
11. Chefetz I., Holmberg J. C., Alvero A. B., Visintin I., Mor G., Inhibition of Aurora-A kinase induces cell cycle arrest in epithelial ovarian cancer stem cells by affecting NF B pathway Cell Cycle 2011 10 13 2206 2214
12. Jones S., Wang T. L., Shih I. M., Mao T. L., Nakayama K., Roden R., Glas R., Slamon D., Diaz L. A., Vogelstein B., Kinzler K. W., Velculescu V. E., Papadopoulos N., Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma Science 2010 330 6001 228 231
13. Wiegand K. C., Shah S. P., Al-Agha O. M., Zhao Y., Tse K., Zeng T., Senz J., McConechy M. K., Anglesio M. S., Kalloger S. E., Yang W., Heravi-Moussavi A., Giuliany R., Chow C., Fee J., Zayed A., Prentice L., Melnyk N., Turashvili G., Delaney A. D., Madore J., Yip S., McPherson A. W., Ha G., Bell L., Fereday S., Tam A., Galletta L., Tonin P. N., Provencher D., Miller D., Jones S. J. M., Moore R. A., Morin G. B., Oloumi A., Boyd N., Aparicio S. A., Shih I. M., Mes-Masson A. M., Bowtell D. D., Hirst M., Gilks B., Marra M. A., Huntsman D. G., ARID1A mutations in endometriosis-associated ovarian carcinomas New England Journal of Medicine 2010 363 16 1532 1543
14. Guan B., Mao T.-L., Panuganti P. K., Kuhn E., Kurman R. J., Maeda D., Chen E., Jeng Y.-M., Wang T.-L., Shih I.-M., Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma American Journal of Surgical Pathology 2011 35 5 625 632
15. Guan B., Wang T.-L., Shih I.-M., ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers Cancer Research 2011 71 21 6718 6727
16. Lu Z., Luo R. Z., Lu Y., Zhang X., Yu Q., Khare S., Kondo S., Kondo Y., Yu Y., Mills G. B., Liao W. S. L., Bast R. C., The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells Journal of Clinical Investigation 2008 118 12 3917 3929
17. Yu Y., Xu F., Peng H., Fang X., Zhao S., Li Y., Cuevas B., Kuo W. L., Gray J. W., Siciliano M., Mills G. B., Bast R. C., NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas Proceedings of the National Academy of Sciences of the United States of America 1999 96 1 214 219 (Pubitemid 29036079)
18. Luo R. Z., Peng H., Xu F., Bao J., Pang Y., Pershad R., Issa J. P. J., Liao W. S. L., Bast R. C., Yu Y., Genomic structure and promoter characterization of an imprinted tumor suppressor gene ARHI Biochimica et Biophysica Acta 2001 1519 3 216 222 (Pubitemid 32545431)
19. Rosen D. G., Wang L., Jain A. N., Lu K. H., Luo R. Z., Yu Y., Liu J., Bast R. C., Expression of the tumor suppressor gene ARHI in epithelial ovarian cancer is associated with increased expression of p21WAF1/CIP1 and prolonged progression-free survival Clinical Cancer Research 2004 10 19 6559 6566 (Pubitemid 39346551)
20. Kondo Y., Kanzawa T., Sawaya R., Kondo S., The role of autophagy in cancer development and response to therapy Nature Reviews Cancer 2005 5 9 726 734 (Pubitemid 41486365)
21. Marx J., Autophagy: is it cancer's friend or foe? Science 2006 312 5777 1160 1161
22. Degenhardt K., Mathew R., Beaudoin B., Bray K., Anderson D., Chen G., Mukherjee C., Shi Y., Gélinas C., Fan Y., Nelson D. A., Jin S., White E., Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis Cancer Cell 2006 10 1 51 64
23. Carew J. S., Nawrocki S. T., Kahue C. N., Zhang H., Yang C., Chung L., Houghton J. A., Huang P., Giles F. J., Cleveland J. L., Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHAto overcome Bcr-Abl-mediated drug resistance Blood 2007 110 1 313 322 (Pubitemid 47026849)
24. Lu Z., Luo R. Z., Lu Y., Zhang X., Yu Q., Khare S., Kondo S., Kondo Y., Yu Y., Mills G. B., Liao W. S., Bast R. C., A novel tumor suppressor gene ARHI induces autophagy and tumor dormancy in ovarian cancer xenografts Journal of Clinical Investigation 2008 118 3917 3929
25. Feng W., Marquez R. T., Lu Z., Liu J., Lu K. H., Issa J. P. J., Fishman D. M., Yu Y., Bast R. C., Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation Cancer 2008 112 7 1489 1502 (Pubitemid 351441161)
26. Rosenberg B., VanCamp L., Trosko J. E., Mansour V. H., Platinum compounds: a new class of potent antitumour agents Nature 1969 222 5191 385 386
27. Helm C. W., States J. C., Enhancing the efficacy of cisplatin in ovarian cancer treatmentcould arsenic have a role Journal of Ovarian Research 2009 2 1, article 2
28. Bristow R. E., Tomacruz R. S., Armstrong D. K., Trimble E. L., Montz F. J., Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis Journal of Clinical Oncology 2002 20 5 1248 1259 (Pubitemid 34177431)
29. Ozols R. F., Bundy B. N., Greer B. E., Fowler J. M., Clarke-Pearson D., Burger R. A., Mannel R. S., DeGeest K., Hartenbach E. M., Baergen R., Mackey D., Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study Journal of Clinical Oncology 2003 21 17 3194 3200 (Pubitemid 46606249)
30. McGuire W. P., Brady M. F., Ozols R. F., The Gynecologic Oncology Group experience in ovarian cancer Annals of Oncology 1999 10 supplement 1 S29 S34 (Pubitemid 29173064)
31. Yoneda J., Kuniyasu H., Crispens M. A., Price J. E., Bucana C. D., Fidler I. J., Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice Journal of the National Cancer Institute 1998 90 6 447 454 (Pubitemid 28160636)
32. Birrer M. J., Johnson M. E., Hao K., Wong K. K., Park D. C., Bell A., Welch W. R., Berkowitz R. S., Mok S. C., Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas Journal of Clinical Oncology 2007 25 16 2281 2287 (Pubitemid 46954656)
33. Monk B. J., Han E., Josephs-Cowan C. A., Pugmire G., Burger R. A., Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytoxic regimens in advanced refractory epithelial ovarian cancer Gynecologic Oncology 2006 102 140 144 (Pubitemid 44056265)
34. Kamat A. A., Kim T. J., Landen C. N., Lu C., Han L. Y., Lin Y. G., Merritt W. M., Thaker P. H., Gershenson D. M., Bischoff F. Z., Heymach J. V., Jaffe R. B., Coleman R. L., Sood A. K., Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer Cancer Research 2007 67 1 281 288 (Pubitemid 46142786)
35. Lu C., Thaker P. H., Lin Y. G., Spannuth W., Landen C. N., Merritt W. M., Jennings N. B., Langley R. R., Gershenson D. M., Yancopoulos G. D., Ellis L. M., Jaffe R. B., Coleman R. L., Sood A. K., Impact of vessel maturation on antiangiogenic therapy in ovarian cancer American Journal of Obstetrics and Gynecology 2008 198 4 477 479
36. Biagi J. J., Oza A. M., ChalChal H. I., Grimshaw R., Ellard S. L., Lee U., Hirte H., Sederias J., Ivy S. P., Eisenhauer E. A., A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC clinical trials group study Annals of Oncology 2011 22 2 335 340
37. Hirte H. W., Vidal L., Fleming G. F., Aphase II study of cediranib (AZD2171) in recurrent or persistent ovarian, peritonealor fallopian tube cancer: final results of aPMH, Chicago and California consortiatrial Proceedings of the 44th American Society of Clinical OncologyAnnual Meeting of the Program and Abstracts May-June 2008 Chicago, Ill, USA
38. Schilder R. J., Sill M. W., Chen X., Darcy K. M., Decesare S. L., Lewandowski G., Lee R. B., Arciero C. A., Wu H., Godwin A. K., Phase II study of gefitinib inpatients with relapsed or persistent ovarian or primaryperitoneal carcinoma and evaluation of epidermalgrowth factor receptor mutations andimmunohistochemical expression: a Gynecologic Oncology Group Study Clinical Cancer Research 2005 11 5539 5548 (Pubitemid 41060831)
39. Gordon A. N., Finkler N., Edwards R. P., Garcia A. A., Crozier M., Irwin D. H., Barrett E., Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study International Journal of Gynecological Cancer 2005 15 5 785 792 (Pubitemid 41783082)
40. Heinemann V., Stintzing S., Kirchner T., Boeck S., Jung A., Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR Cancer Treatment Reviews 2009 35 3 262 271
41. Cho H. S., Mason K., Ramyar K. X., Stanley A. M., Gabelli S. B., Denney D. W., Leahy D. J., Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab Nature 2003 421 6924 756 760 (Pubitemid 36227628)
42. Franklin M. C., Carey K. D., Vajdos F. F., Leahy D. J., De Vos A. M., Sliwkowski M. X., Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex Cancer Cell 2004 5 4 317 328 (Pubitemid 38482068)
43. Makhija S., Amler L. C., Glenn D., Ueland F. R., Gold M. A., Dizon D. S., Paton V., Lin C. Y., Januario T., Ng K., Strauss A., Kelsey S., Sliwkowski M. X., Matulonis U., Clinical activity of gemcitabine plus pertuzumab in platinum-resistant ovarian cancer, fallopian tube cancer, or primary peritoneal cancer Journal of Clinical Oncology 2010 28 7 1215 1223
44. Kaye S. B., Poole C. J., Bidzinksi M., A randomised phase II study evaluating the combination of carboplatin-based chemotherapy with pertuzumab versus carboplatin based therapy alone in patients with relapsed, platinum sensitive ovarian cancer Journal of Clinical Oncology 2008 26, abstract 5520
45. Faratian D., Zweemer A. J.M., Nagumo Y., Sims A. H., Muir M., Dodds M., Mullen P., Um I., Kay C., Hasmann M., Harrison D. J., Langdon S. P., Trastuzumab and pertuzumab produce changes in morphology and estrogen receptor signaling in ovarian cancer xenografts revealing new treatment strategies Clinical Cancer Research 2011 17 13 4451 4461
46. Hu L., Hofmann J., Lu Y., Mills G. B., Jaffe R. B., Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models Cancer Research 2002 62 4 1087 1092 (Pubitemid 34160292)
47. Raynaud F. I., Eccles S., Clarke P. A., Hayes A., Nutley B., Alix S., Henley A., Di-Stefano F., Ahmad Z., Guillard S., Bjerke L. M., Kelland L., Valenti M., Patterson L., Gowan S., Brandon A. D. H., Hayakawa M., Kaizawa H., Koizumi T., Ohishi T., Patel S., Saghir N., Parker P., Waterfield M., Workman P., Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases Cancer Research 2007 67 12 5840 5850 (Pubitemid 46985018)
48. McMurray J. S., A new small-molecule Stat3 inhibitor Chemistry and Biology 2006 13 11 1123 1124 (Pubitemid 44750737)
49. Beck H. P., Kohn T., Rubenstein S., Hedberg C., Schwandner R., Hasslinger K., Dai K., Li C., Liang L., Wesche H., Frank B., An S., Wickramasinghe D., Jaen J., Medina J., Hungate R., Shen W., Discovery of potent LPA 2 (EDG4) antagonists as potential anticancer agents Bioorganic and Medicinal Chemistry Letters 2008 18 3 1037 1041 (Pubitemid 351179347)
50. Lin Y. G., Kunnumakkara A. B., Nair A., Merritt W. M., Han L. Y., Armaiz-Pena G. N., Kamat A. A., Spannuth W. A., Gershenson D. M., Lutgendorf S. K., Aggarwal B. B., Sood A. K., Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor- B pathway Clinical Cancer Research 2007 13 11 3423 3430 (Pubitemid 46944931)
51. Samanta A. K., Huang H. J., Bast R. C., Liao W. S. L., Overexpression of MEKK 3 confers resistance to apoptosis through activation of NF B Journal of Biological Chemistry 2004 279 9 7576 7583 (Pubitemid 38294636)
52. Karin M., Nuclear factor- B in cancer development and progression Nature 2006 441 7092 431 436 (Pubitemid 44050137)
53. Ashworth A., A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair Journal of Clinical Oncology 2008 26 22 3785 3790
54. Fong P. C., Boss D. S., Carden C. P., AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: results from a phase I study Journal of Clinical Oncology 2008 26, abstract 5510
55. Mangerich A., Brkle A., How to kill tumor cells with inhibitors of poly(ADP-ribosyl)ation International Journal of Cancer 2011 128 2 251 265
56. Denko N. C., Hypoxia, HIF1 and glucose metabolism in the solid tumour Nature Reviews Cancer 2008 8 9 705 713
57. Gambhir S. S., Molecular imaging of cancer with positron emission tomography Nature Reviews Cancer 2002 2 9 683 693 (Pubitemid 37328919)
58. Mankoff D. A., Eary J. F., Link J. M., Muzi M., Rajendran J. G., Spence A. M., Krohn K. A., Tumor-specific positron emission tomography imaging in patients: [ 18 F] fluorodeoxyglucose and beyond Clinical Cancer Research 2007 13 12 3460 3469 (Pubitemid 46955105)
59. Kroemer G., Pouyssegur J., Tumor cell metabolism: cancer's achilles' heel Cancer Cell 2008 13 6 472 482 (Pubitemid 351766797)
60. Hsu P. P., Sabatini D. M., Cancer cell metabolism: warburg and beyond Cell 2008 134 5 703 707
61. Favaro E., Nardo G., Persano L., Masiero M., Moserle L., Zamarchi R., Rossi E., Esposito G., Plebani M., Sattler U., Mann T., Mueller-Klieser W., Ciminale V., Amadori A., Indraccolo S., Hypoxia inducible factor-1 inactivation unveils a link between tumor cell metabolism and hypoxia-induced cell death American Journal of Pathology 2008 173 4 1186 1201
62. Shimogai R., Kigawa J., Itamochi H., Iba T., Kanamori Y., Oishi T., Shimada M., Sato S., Kawaguchi W., Sato S., Terakawa N., Expression of hypoxia-inducible factor 1 gene affects the outcome in patients with ovarian cancer International Journal of Gynecological Cancer 2008 18 3 499 505 (Pubitemid 351668322)
63. Emerling B. M., Platanias L. C., Black E., Nebreda A. R., Davis R. J., Chandel N. S., Mitochondrial reactive oxygen species activation of p38 mitogen-activated protein kinase is required for hypoxia signaling Molecular and Cellular Biology 2005 25 12 4853 4862 (Pubitemid 40781087)
64. Kwon S. J., Song J. J., Lee Y. J., Signal pathway of hypoxia-inducible factor-1 phosphorylation and its interaction with von Hippel-Lindau tumor suppressor protein during ischemia in MiaPaCa-2 pancreatic cancer cells Clinical Cancer Research 2005 11 21 7607 7613 (Pubitemid 41611600)
65. Chiacchiera F., Simone C., Signal-dependent regulation of gene expression as a target for cancer treatment: inhibiting p38 in colorectal tumors Cancer Letters 2008 265 1 16 26
66. Comes F., Matrone A., Lastella P., Nico B., Susca F. C., Bagnulo R., Ingravallo G., Modica S., Lo Sasso G., Moschetta A., Guanti G., Simone C., A novel cell type-specific role of p38 in the control of autophagy and cell death in colorectal cancer cells Cell Death and Differentiation 2007 14 4 693 702 (Pubitemid 46444507)
67. Simone C., Signal-dependent control of autophagy and cell death in colorectal cancer cell: the role of the p38 pathway Autophagy 2007 3 5 468 471 (Pubitemid 47293729)
68. Chiacchiera F., Matrone A., Ferrari E., Ingravallo G., Lo Sasso G., Murzilli S., Petruzzelli M., Salvatore L., Moschetta A., Simone C., p38 blockade inhibits colorectal cancer growth in vivo by inducing a switch from HIF1 -to FoxO-dependent transcription Cell Death and Differentiation 2009 16 9 1203 1214
69. Chiacchiera F., Simone C., Inhibition of p38 unveils an AMPK-FoxO3A axis linking autophagy to cancer-specific metabolism Autophagy 2009 5 7 1030 1033
70. Matrone A., Grossi V., Chiacchiera F., Fina E., Cappellari M., Caringella A. M., Di Naro E., Loverro G., Simone C., P38 is required for ovarian cancer cell metabolism and survival International Journal of Gynecological Cancer 2010 20 2 203 211
71. Yang S. Y., Miah A., Sales K. M., Fuller B., Seifalian A. M., Winslet M., Inhibition of the p38 MAPK pathway sensitises human colon cancer cells to 5-fluorouracil treatment International Journal of Oncology 2011 38 6 1695 1702
72. Paillas S., Boissire F., Bibeau F., Denouel A., Mollevi C., Causse A., Denis V., Vezzio-Vié N., Marzi L., Cortijo C., Ait-Arsa I., Askari N., Pourquier P., Martineau P., Del Rio M., Gongora C., Targeting the p38 MAPK pathway inhibits irinotecan resistance in colon adenocarcinoma Cancer Research 2011 71 3 1041 1049
73. Wagner E. F., Nebreda A. R., Signal integration by JNK and p38 MAPK pathways in cancer development Nature Reviews Cancer 2009 9 8 537 549